Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204749 · ClinicalTrials.gov registry record · Phase 3
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 919
- Enrollment target
NCT01204749 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 919 participants.
The verdict
NCT01204749, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 919 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Interventions
- DRUG Paclitaxel
- DRUG AMG 386
- DRUG AMG 386 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 919 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204749
The ClinicalTrials.gov registry entry for NCT01204749 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 919 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT01204749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204749 about?
NCT01204749 is a clinical study titled "TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer". The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medicatio...
What is the current status of trial NCT01204749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 919 participants. The study started on 2010-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01204749?
The interventions under investigation include: Paclitaxel (DRUG), AMG 386 (DRUG), AMG 386 Placebo (DRUG).
Who is sponsoring clinical trial NCT01204749?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.